Literature DB >> 12034689

Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia.

M Flynn Roberts1, G A Fishman, D K Roberts, J R Heckenlively, R G Weleber, R J Anderson, S Grover.   

Abstract

BACKGROUND/AIMS: Few studies have reported on the change in visual acuity (VA) in patients with choroideraemia. In order to determine the degree and rate of VA impairment associated with this disease, the central VA was analysed in a large group of patients with choroideraemia.
METHODS: The authors completed a retrospective, cross sectional review of 115 patients with choroideraemia from three tertiary care centres. A longitudinal analysis was performed on 45 of these patients who met the inclusion criteria of at least three visits over a minimum period of 4.5 years. Multiple linear regression analysis was used to explore the 5 year rate of VA change while controlling for initial VA and initial age. Multiple logistic regression was also used to investigate VA impairment.
RESULTS: In the cross sectional group (n = 115), 84% (87/103) of patients under the age of 60 had a VA of 20/40 or better while 33% (4/12) of patients 60 years of age or older had a VA of 20/200 or worse at their most recent visit. The majority of the patients (93%) in the longitudinal subgroup of 45 patients had a VA of 20/30 or better at their initial visit. The mean 5 year rate of VA change was 0.09 logMAR equivalent (approximately one line on the Lighthouse chart).
CONCLUSION: In this cohort of patients with choroideraemia, there was typically a slow rate of VA loss and the prognosis for central VA retention was, as a group, favourable until the seventh decade.

Entities:  

Mesh:

Year:  2002        PMID: 12034689      PMCID: PMC1771148          DOI: 10.1136/bjo.86.6.658

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

1.  A hereditary and clinical study of choroideremia.

Authors:  C McCULLOCH; R J P McCULLOCH
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1948 Jan-Feb

2.  Choroideremia: a study of two families.

Authors:  C K Cheng; M S Chen; P K Hou
Journal:  J Formos Med Assoc       Date:  1991-11       Impact factor: 3.282

3.  Reproducibility of visual acuity measurements in patients with retinitis pigmentosa.

Authors:  S Grover; G A Fishman; L D Gilbert; R J Anderson
Journal:  Retina       Date:  1997       Impact factor: 4.256

Review 4.  Molecular basis of choroideremia (CHM): mutations involving the Rab escort protein-1 (REP-1) gene.

Authors:  J A van den Hurk; M Schwartz; H van Bokhoven; T J van de Pol; L Bogerd; A J Pinckers; E M Bleeker-Wagemakers; I H Pawlowitzki; K Rüther; H H Ropers; F P Cremers
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

5.  Choroideremia. A clinical and genetic study of 84 Finnish patients and 126 female carriers.

Authors:  J Kärnä
Journal:  Acta Ophthalmol Suppl       Date:  1986

6.  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1985-12

7.  Deficient geranylgeranylation of Ram/Rab27 in choroideremia.

Authors:  M C Seabra; Y K Ho; J S Anant
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

  7 in total
  39 in total

1.  Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia.

Authors:  Mohamed A Genead; Jason J McAnany; Gerald A Fishman
Journal:  Retina       Date:  2012-04       Impact factor: 4.256

2.  Retinal dystrophy and subretinal drusenoid deposits in female choroideremia carriers.

Authors:  Vittoria Murro; Dario Pasquale Mucciolo; Ilaria Passerini; Simona Palchetti; Andrea Sodi; Gianni Virgili; Stanislao Rizzo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-27       Impact factor: 3.117

3.  Long-term Natural History of Atrophy in Eyes with Choroideremia-A Systematic Review and Meta-analysis of Individual-Level Data.

Authors:  Liangbo L Shen; Aneesha Ahluwalia; Mengyuan Sun; Benjamin K Young; Holly K Grossetta Nardini; Lucian V Del Priore
Journal:  Ophthalmol Retina       Date:  2020-03-14

4.  Multimodal assessment of choroideremia patients defines pre-treatment characteristics.

Authors:  Immanuel P Seitz; Ahmad Zhour; Susanne Kohl; Pablo Llavona; Tobias Peter; Barbara Wilhelm; Eberhart Zrenner; Marius Ueffing; Karl Ulrich Bartz-Schmidt; M Dominik Fischer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-03-07       Impact factor: 3.117

5.  Natural History of the Central Structural Abnormalities in Choroideremia: A Prospective Cross-Sectional Study.

Authors:  Tomas S Aleman; Grace Han; Leona W Serrano; Nicole M Fuerst; Emily S Charlson; Denise J Pearson; Daniel C Chung; Anastasia Traband; Wei Pan; Gui-Shuang Ying; Jean Bennett; Albert M Maguire; Jessica I W Morgan
Journal:  Ophthalmology       Date:  2016-12-13       Impact factor: 12.079

6.  CHOROIDEREMIA: Retinal Degeneration With an Unmet Need.

Authors:  Mark E Pennesi; David G Birch; Jacque L Duncan; Jean Bennett; Aniz Girach
Journal:  Retina       Date:  2019-11       Impact factor: 4.256

7.  Long-term follow-up of vitrectomy in patients with pathologic myopic foveoschisis.

Authors:  Ting Zhang; Ying Zhu; Chun-Hui Jiang; Ge-Zhi Xu
Journal:  Int J Ophthalmol       Date:  2017-02-18       Impact factor: 1.779

8.  Clinical characteristics of a large choroideremia pedigree carrying a novel CHM mutation.

Authors:  Alex S Huang; Leo A Kim; Amani A Fawzi
Journal:  Arch Ophthalmol       Date:  2012-09

9.  [Hereditary retinochoroidal dystrophies. Part 2: differential diagnosis].

Authors:  U Kellner; A B Renner; H Tillack
Journal:  Ophthalmologe       Date:  2004-04       Impact factor: 1.059

10.  Rose Bengal Photodynamic Antimicrobial Therapy for Patients With Progressive Infectious Keratitis: A Pilot Clinical Study.

Authors:  Andrea Naranjo; Alejandro Arboleda; Jaime D Martinez; Heather Durkee; Mariela C Aguilar; Nidhi Relhan; Neda Nikpoor; Anat Galor; Sander R Dubovy; Roger Leblanc; Harry W Flynn; Darlene Miller; Jean-Marie Parel; Guillermo Amescua
Journal:  Am J Ophthalmol       Date:  2019-09-05       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.